Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.35 |
| ▸ | EED | O75530 | 2/20 | 0.33 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.33 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.33 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 0.33 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785590 | 0.88 | EZH2 (0.37) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL31474602 | 0.74 | EZH2 (0.31) | EZH2 | |
| SCHEMBL31474608 | 0.71 | OPRM1 (0.34) | EZH2 | |
| SCHEMBL22734113 | 0.69 | LMNA (0.37) | — | |
| SCHEMBL31491369 | 0.68 | CD38 (0.35) | — | |
| SCHEMBL18455533 | 0.67 | HPGD (0.53) | KDM4EALDH1A1TP53GLAGAA | |
| SCHEMBL22734117 | 0.67 | KMT2A (0.34) | — | |
| SCHEMBL31491326 | 0.66 | — | — | |
| SCHEMBL22734112 | 0.66 | ESR1 (0.40) | — | |
| SCHEMBL31670501 | 0.66 | EZH2 (0.38) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4596554-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Suzhou Arkbiopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| CN-119698422-A | Aza condensed ring compound, preparation method and medical application thereof | 苏州爱科百发生物医药技术有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024067660-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 苏州爱科百发生物医药技术有限公司 | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | KDM4E 984/4885ALDH1A1 693/4885TP53 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.